phase readout
saveNCT07233213: An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Grand Shuyang Life Sciences (Chengdu) Co., Ltd.. Phase: PHASE3. Conditions: Primary Immune Thrombocytopenia (ITP)
view source ↗
comments(0)
5-min edit window · permanent after that